Related Experiment Video

Updated: Feb 23, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

BH3 Mimetics for the Treatment of Prostate Cancer

Philipp Wolf1

  • 1Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine, University of FreiburgFreiburg, Germany.

Frontiers in Pharmacology
|September 5, 2017
PubMed

Insights

Advanced prostate cancer (PC) is incurable due to apoptosis resistance. BH3 mimetics offer a promising strategy by targeting anti-apoptotic proteins, potentially sensitizing cancer cells to cell death for future PC therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced prostate cancer (PC) remains incurable despite advancements.
  • Treatment resistance in PC is linked to apoptosis resistance via Bcl-2 family proteins.

Purpose of the Study:

  • To review preclinical and clinical studies of BH3 mimetics in advanced PC.
  • To explore the potential of BH3 mimetics as sensitizers for cell death in PC therapy.

Main Methods:

  • Review of existing literature on BH3 mimetics.
  • Analysis of preclinical and clinical trial data.
  • Focus on pan- and specific BH3 mimetics targeting the intrinsic apoptotic pathway.

Main Results:

  • BH3 mimetics show promise in sensitizing cancer cells to apoptosis.
  • Upregulation of anti-apoptotic proteins contributes to treatment resistance in PC.
  • BH3 mimetics mimic pro-apoptotic proteins to overcome resistance.

Conclusions:

  • BH3 mimetics represent a promising therapeutic strategy for advanced prostate cancer.
  • Effective utilization of BH3 mimetics could enhance future PC treatment protocols.
  • Targeting apoptosis pathways is crucial for overcoming treatment resistance in PC.
Keywords:
BH3 mimeticsBcl-2 proteinsapoptosisprostate cancertherapeutic resistance

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.1K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K